Orphan designation: golcadomide hydrochloride Treatment of diffuse large B-cell lymphoma, 12/01/2024 Positive
Orphan designation: golcadomide hydrochloride Treatment of diffuse large B-cell lymphoma, 12/01/2024 Positive
Orphan designation: golcadomide hydrochloride Treatment of diffuse large B-cell lymphoma, 12/01/2024 Positive
Orphan designation: Human coagulation factor X Treatment of acquired factor X deficiency, 12/01/2024 Positive
Orphan designation: (4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-1-carboximidamide hydrochloride Treatment of systemic sclerosis, 12/01/2024 Positive
Orphan designation: mRNA encoding the human CFTR gene Treatment of cystic fibrosis, 19/02/2024 Positive
Human medicines European public assessment report (EPAR): Ambrisentan Mylan, ambrisentan, Date of authorisation: 20/06/2019, Revision: 5, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Tessie, tasipimidine, Status: Authorised
EMA/FVE info session on restrictions of certain antimicrobials, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 15:00 (CEST) to 23 May 2024, 16:00 (CEST)
Human medicines European public assessment report (EPAR): Ranexa (previously Latixa), ranolazine, Date of authorisation: 08/07/2008, Revision: 23, Status: Authorised
Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)
Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Date of authorisation: 23/10/2001, Revision: 33, Status: Authorised